Figure 2.
Cytokine profiling. (A) IL15 during the first month after CAR19-22 infusion. Shown are medians and interquartile ranges for MFIs of IL15 for control patients (red) and those treated with NKTR-255 (blue). NKTR-255 administration is denoted by the red dashed line. The number of observations at each time point is shown below the graph. “PLD” indicates time points before lymphodepleting chemotherapy. Control patients did not have samples at day +15 or +16 available for analysis. Cytokine levels before and after NKTR-255 administration for patients with both samples available for analysis. (B) Comparison of day +14 preinfusion with postinfusion values (n = 8); (C) comparison day +14 preinfusion with day +15 values (n = 6). P values were calculated with the paired Mann-Whitney U test. Cytokines were grouped according to common γ-chain cytokines (top), interferon-γ–related (middle), and proinflammatory cytokines (bottom).

Cytokine profiling. (A) IL15 during the first month after CAR19-22 infusion. Shown are medians and interquartile ranges for MFIs of IL15 for control patients (red) and those treated with NKTR-255 (blue). NKTR-255 administration is denoted by the red dashed line. The number of observations at each time point is shown below the graph. “PLD” indicates time points before lymphodepleting chemotherapy. Control patients did not have samples at day +15 or +16 available for analysis. Cytokine levels before and after NKTR-255 administration for patients with both samples available for analysis. (B) Comparison of day +14 preinfusion with postinfusion values (n = 8); (C) comparison day +14 preinfusion with day +15 values (n = 6). P values were calculated with the paired Mann-Whitney U test. Cytokines were grouped according to common γ-chain cytokines (top), interferon-γ–related (middle), and proinflammatory cytokines (bottom).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal